Effects of bamlanivimab alone or in combination with etesevimab on subsequent hospitalization and mortality in outpatients with COVID-19: a systematic review and meta-analysis

BACKGROUND: Coronavirus disease 2019 (COVID-19) has caused an enormous loss of life worldwide. The spike protein of the severe acute respiratory syndrome coronavirus 2 is the cause of its virulence. Bamlanivimab, a recombinant monoclonal antibody, has been used alone or in combination with etesevima...

Descripción completa

Detalles Bibliográficos
Autores principales: Tai, Yu-Lin, Lee, Ming-Dar, Chi, Hsin, Chiu, Nan-Chang, Lei, Wei-Te, Weng, Shun-Long, Liu, Lawrence Yu-Min, Chen, Chung-Chu, Huang, Shih-Yu, Huang, Ya-Ning, Lin, Chien-Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2023
Materias:
Drugs and Devices
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10174063/
https://www.ncbi.nlm.nih.gov/pubmed/37180576
http://dx.doi.org/10.7717/peerj.15344

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10174063/
https://www.ncbi.nlm.nih.gov/pubmed/37180576
http://dx.doi.org/10.7717/peerj.15344

Ejemplares similares